1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Albiges, H.P. Gurney, V. Atduev, Cynthia Suárez, M.A. Climent Duran, D. Pook, P. Tomczak, P. Barthelemy, Jia-Lin Lee, Taron Nalbandian, V. Stus, T. Ferguson, P. Wiechno, E. Gokmen, L. Lacombe, C. Gedye, R. Perini, M. Sharma, C. Li, Chi‐Hang Lee